Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03735290
Title A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer (ILIAD)
Acronym ILIAD
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Immunicum AB
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.